Solvay Pharmaceuticals is determined to attain a prominent presence in the field that deals with the world’s number one cause of death, the cardiovascular area. Important results have already been achieved in this area.
With the acquisition of Fournier Pharma, Solvay Pharmaceuticals has become the global leader in fenofibrate, a successful cardio-metabolic product for treating aised blood lipids. The integration of Fournier Pharma adds a strong and unique product line in dyslipidemia (i.e. control of cholesterol and triglycerides) to Solvay’s cardiology business making this new cardio-metabolic area our largest franchise.
